drugset / Trial / NCT03877406
Effect of Empagliflozin on Body Composition and Ketones
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).
Timeline
- Start
- 2018-08-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | — |